MENU
OGN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

OGN stock forecast, quote, news & analysis

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day... Show more

A.I.Advisor
published price charts
OGN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for OGN with price predictions
Oct 21, 2026

Momentum Indicator for OGN turns negative, indicating new downward trend

OGN saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 50 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 54 cases where OGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for OGN turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 21 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

OGN broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a +0.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in 183 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 90 of 235 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. OGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.589) is normal, around the industry mean (-3.196). P/E Ratio (17.405) is within average values for comparable stocks, (21.213). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.006) settles around the average of (0.041) among similar stocks. OGN's P/S Ratio (0.589) is slightly lower than the industry average of (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

A.I.Advisor
published Dividends

OGN paid dividends on September 10, 2026

Organon & Co OGN Stock Dividends
А dividend of $0.02 per share was paid with a record date of September 10, 2026, and an ex-dividend date of August 14, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 206.81B. The market cap for tickers in the group ranges from 4.8K to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 6%. LLY experienced the highest price growth at 5%, while MDCX experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -38% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 36
Price Growth Rating: 44
SMR Rating: 59
Profit Risk Rating: 61
Seasonality Score: 4 (-100 ... +100)
Momentum Indicator for OGN turns negative, indicating new downward trend